Whither high-dose chemotherapy in breast cancer?


:Four trials of high-dose chemotherapy with stem cell support in breast cancer in the adjuvant and metastatic settings have shown no long-term disease-free or overall survival gain. This relative failure of a single high-dose therapy we believe opens up the development of a dose-dense approach with block scheduling as the most promising way forward. This intensive chemotherapy can be more easily combined with the newer biological therapies and our prediction is that this will prove to be the most effective treatment in the future for women with poor risk breast cancer.


Breast Cancer Res


Mayer A,Earl H





Has Abstract


2001-01-01 00:00:00












  • GATA3 protein as a MUC1 transcriptional regulator in breast cancer cells.

    abstract:INTRODUCTION:Recent studies have demonstrated that members of the GATA-binding protein (GATA) family (GATA4 and GATA5) might have pivotal roles in the transcriptional upregulation of mucin genes (MUC2, MUC3 and MUC4) in gastrointestinal epithelium. The zinc-finger GATA3 transcription factor has been reported to be invo...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Abba MC,Nunez MI,Colussi AG,Croce MV,Segal-Eiras A,Aldaz CM

    更新日期:2006-01-01 00:00:00

  • Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin.

    abstract:INTRODUCTION:Breast cancers frequently metastasise to the skeleton where they cause osteolytic bone destruction by stimulating osteoclasts to resorb bone and by preventing osteoblasts from producing new bone. The Runt-related transcription factor 2, Runx2, is an important determinant of bone metastasis in breast cancer...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Mendoza-Villanueva D,Zeef L,Shore P

    更新日期:2011-10-27 00:00:00

  • Role of ADAM17 in the non-cell autonomous effects of oncogene-induced senescence.

    abstract:INTRODUCTION:Cellular senescence is a terminal cell proliferation arrest that can be triggered by oncogenes. One of the traits of oncogene-induced senescence (OIS) is the so-called senescence-associated secretory phenotype or senescence secretome. Depending on the context, the non-cell autonomous effects of OIS may var...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Morancho B,Martínez-Barriocanal Á,Villanueva J,Arribas J

    更新日期:2015-08-12 00:00:00

  • The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer.

    abstract::Testosterone binds to the androgen receptor in target tissue to mediate its effects. Variations in testosterone levels and androgen receptor activity may play a role in the etiology of breast cancer. Here, we review the epidemiologic evidence linking endogenous testosterone to breast cancer risk. Paradoxically, result...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审


    authors: Lillie EO,Bernstein L,Ursin G

    更新日期:2003-01-01 00:00:00

  • An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers.

    abstract:INTRODUCTION:Individuals carrying pathogenic mutations in the BRCA1 and BRCA2 genes have a high lifetime risk of breast cancer. BRCA1 and BRCA2 are involved in DNA double-strand break repair, DNA alterations that can be caused by exposure to reactive oxygen species, a main source of which are mitochondria. Mitochondria...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Blein S,Bardel C,Danjean V,McGuffog L,Healey S,Barrowdale D,Lee A,Dennis J,Kuchenbaecker KB,Soucy P,Terry MB,Chung WK,Goldgar DE,Buys SS,Breast Cancer Family Registry.,Janavicius R,Tihomirova L,Tung N,Dorfling CM,va

    更新日期:2015-04-25 00:00:00

  • Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways.

    abstract:INTRODUCTION:Mammary-specific overexpression of Six1 in mice induces tumors that resemble human breast cancer, some having undergone epithelial to mesenchymal transition (EMT) and exhibiting stem/progenitor cell features. Six1 overexpression in human breast cancer cells promotes EMT and metastatic dissemination. We hyp...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Iwanaga R,Wang CA,Micalizzi DS,Harrell JC,Jedlicka P,Sartorius CA,Kabos P,Farabaugh SM,Bradford AP,Ford HL

    更新日期:2012-07-05 00:00:00

  • Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo.

    abstract:INTRODUCTION:Triple-negative breast cancer does not express estrogen and progesterone receptors, and no overexpression/amplification of the HER2-neu gene occurs. Therefore, this subtype of breast cancer lacks the benefits of specific therapies that target these receptors. Today chemotherapy is the only systematic thera...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Gründker C,Föst C,Fister S,Nolte N,Günthert AR,Emons G

    更新日期:2010-01-01 00:00:00

  • CRIPTO antagonist ALK4L75A-Fc inhibits breast cancer cell plasticity and adaptation to stress.

    abstract:BACKGROUND:CRIPTO is a multi-functional signaling protein that promotes stemness and oncogenesis. We previously developed a CRIPTO antagonist, ALK4L75A-Fc, and showed that it causes loss of the stem cell phenotype in normal mammary epithelia suggesting it may similarly inhibit CRIPTO-dependent plasticity in breast canc...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Balcioglu O,Heinz RE,Freeman DW,Gates BL,Hagos BM,Booker E,Mirzaei Mehrabad E,Diesen HT,Bhakta K,Ranganathan S,Kachi M,Leblanc M,Gray PC,Spike BT

    更新日期:2020-11-13 00:00:00

  • Progesterone receptors--animal models and cell signalling in breast cancer. Diverse activation pathways for the progesterone receptor: possible implications for breast biology and cancer.

    abstract::Progesterone and estradiol, and their nuclear receptors, play essential roles in the physiology of the reproductive tract, the mammary gland and the nervous system. Estrogens have traditionally been considered associated with an increased risk of breast cancer. There is, however, compelling evidence that progesterone ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审


    authors: Lanari C,Molinolo AA

    更新日期:2002-01-01 00:00:00

  • Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15.

    abstract:INTRODUCTION:Molecular apocrine (MA) tumors are estrogen receptor (ER) negative breast cancers characterized by androgen receptor (AR) expression. We analyzed a group of 58 transcriptionally defined MA tumors and proposed a new tool to identify these tumors. METHODS:We performed quantitative reverse transcription PCR ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Lehmann-Che J,Hamy AS,Porcher R,Barritault M,Bouhidel F,Habuellelah H,Leman-Detours S,de Roquancourt A,Cahen-Doidy L,Bourstyn E,de Cremoux P,de Bazelaire C,Albiter M,Giacchetti S,Cuvier C,Janin A,Espié M,de Thé H,Bert

    更新日期:2013-05-11 00:00:00

  • Sulfatide decreases the resistance to stress-induced apoptosis and increases P-selectin-mediated adhesion: a two-edged sword in breast cancer progression.

    abstract:BACKGROUND:We have previously shown that galactosylceramide (GalCer) affects the tumourigenic and metastatic properties of breast cancer cells by acting as an anti-apoptotic molecule. Since GalCer is a precursor molecule in the synthesis of sulfatides, the present study was aimed to define the role of sulfatides in apo...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Suchanski J,Grzegrzolka J,Owczarek T,Pasikowski P,Piotrowska A,Kocbach B,Nowak A,Dziegiel P,Wojnar A,Ugorski M

    更新日期:2018-11-06 00:00:00

  • Red-clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial [ISRCTN42940165].

    abstract:INTRODUCTION:Isoflavones are hypothesized to protect against breast cancer, but it is not clear whether they act as oestrogens or anti-oestrogens in breast tissue. Our aim was to determine the effects of taking a red clover-derived isoflavone supplement daily for 1 year on mammographic breast density. Effects on oestra...

    journal_title:Breast cancer research : BCR

    pub_type: 临床试验,杂志文章,随机对照试验


    authors: Atkinson C,Warren RM,Sala E,Dowsett M,Dunning AM,Healey CS,Runswick S,Day NE,Bingham SA

    更新日期:2004-01-01 00:00:00

  • Breast carcinoma and Lynch syndrome: molecular analysis of tumors arising in mutation carriers, non-carriers, and sporadic cases.

    abstract:INTRODUCTION:Breast carcinoma is the most common cancer in women, but its incidence is not increased in Lynch syndrome (LS) and studies on DNA mismatch repair deficiency (MMR) in LS-associated breast cancers have arrived at conflicting results. This study aimed to settle the question as to whether breast carcinoma belo...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Lotsari JE,Gylling A,Abdel-Rahman WM,Nieminen TT,Aittomäki K,Friman M,Pitkänen R,Aarnio M,Järvinen HJ,Mecklin JP,Kuopio T,Peltomäki P

    更新日期:2012-06-12 00:00:00

  • Breast cancer intra-tumor heterogeneity.

    abstract::In recent years it has become clear that cancer cells within a single tumor can display striking morphological, genetic and behavioral variability. Burgeoning genetic, epigenetic and phenomenological data support the existence of intra-tumor genetic heterogeneity in breast cancers; however, its basis is yet to be full...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审


    authors: Martelotto LG,Ng CK,Piscuoglio S,Weigelt B,Reis-Filho JS

    更新日期:2014-05-20 00:00:00

  • CXCL17-derived CD11b+Gr-1+ myeloid-derived suppressor cells contribute to lung metastasis of breast cancer through platelet-derived growth factor-BB.

    abstract:BACKGROUND:Metastasis is the major cause of death from breast cancer. Colonization and adaption of metastatic cells in distant organs is a rate-limiting step of the cancer spreading. The underlying mechanisms responsible for the colonization of breast cancer to lung metastatic niches are not fully understood. METHODS:...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Hsu YL,Yen MC,Chang WA,Tsai PH,Pan YC,Liao SH,Kuo PL

    更新日期:2019-02-12 00:00:00

  • Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.

    abstract:BACKGROUND:The Cancer Genome Atlas analysis revealed that somatic EGFR, receptor tyrosine-protein kinase erbB-2 (ERBB2), Erb-B2 receptor tyrosine kinase 3 (ERBB3) and Erb-B2 receptor tyrosine kinase 4 (ERBB4) gene mutations (ERBB family mutations) occur alone or co-occur with somatic mutations in the gene encoding the ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,随机对照试验


    authors: Toomey S,Eustace AJ,Fay J,Sheehan KM,Carr A,Milewska M,Madden SF,Teiserskiene A,Kay EW,O'Donovan N,Gallagher W,Grogan L,Breathnach O,Walshe J,Kelly C,Moulton B,Kennedy MJ,Gullo G,Hill AD,Power C,Duke D,Hambly N

    更新日期:2017-07-27 00:00:00

  • Trastuzumab emtansine: mechanisms of action and drug resistance.

    abstract::Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that is effective and generally well tolerated when administered as a single agent to treat advanced breast cancer. Efficacy has now been demonstrated in randomized trials as first line, second line, and later than the second line treatment of advanced breast...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审


    authors: Barok M,Joensuu H,Isola J

    更新日期:2014-03-05 00:00:00

  • Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?

    abstract::Anti-angiogenic therapies have demonstrated their value in the setting of advanced cancer, and are being explored for use in micrometastatic disease. Recent preclinical studies suggest that adjuvant anti-vascular endothelial growth factor (VEGF) therapies may increase the risk of metastasis. How concerning are these p...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Schneider BP,Sledge GW Jr

    更新日期:2009-01-01 00:00:00

  • Tricho-rhino-phalangeal syndrome 1 protein functions as a scaffold required for ubiquitin-specific protease 4-directed histone deacetylase 2 de-ubiquitination and tumor growth.

    abstract:BACKGROUND:Although numerous studies have reported that tricho-rhino-phalangeal syndrome type I (TRPS1) protein, the only reported atypical GATA transcription factor, is overexpressed in various carcinomas, the underlying mechanism(s) by which it contributes to cancer remain unknown. METHODS:Both overexpression and kn...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Wang Y,Zhang J,Wu L,Liu W,Wei G,Gong X,Liu Y,Ma Z,Ma F,Thiery JP,Chen L

    更新日期:2018-08-02 00:00:00

  • The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells.

    abstract:INTRODUCTION:Microtubule-associated protein tau (MAPT) inhibits the function of taxanes and high expression of MAPT decreases the sensitivity to taxanes. The relationship between estrogen receptor (ER) and MAPT in breast cancer is unclear. In this study, we examined the correlation of MAPT expression with the sensitivi...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Ikeda H,Taira N,Hara F,Fujita T,Yamamoto H,Soh J,Toyooka S,Nogami T,Shien T,Doihara H,Miyoshi S

    更新日期:2010-01-01 00:00:00

  • Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer.

    abstract:INTRODUCTION:Hypoxia-inducible factor (HIF)-1alpha levels in invasive breast carcinoma have been shown to be an adverse prognostic indicator. Cellular HIF-1alpha activity is regulated by factor-inhibiting hypoxia-inducible factor 1 (FIH-1). In hypoxia, FIH-1 hydroxylation of Asn803 within the C-terminal transactivation...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Tan EY,Campo L,Han C,Turley H,Pezzella F,Gatter KC,Harris AL,Fox SB

    更新日期:2007-01-01 00:00:00

  • Epigenetics in breast cancer: what's new?

    abstract::Epigenetic changes are critical for development and progression of cancers, including breast cancer. Significant progress has been made in the basic understanding of how various epigenetic changes such as DNA methylation, histone modification, miRNA expression, and higher order chromatin structure affect gene expressi...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审


    authors: Huang Y,Nayak S,Jankowitz R,Davidson NE,Oesterreich S

    更新日期:2011-01-01 00:00:00

  • BRCA1 and BRCA2 mutations in a population-based study of male breast cancer.

    abstract:BACKGROUND:The contribution of BRCA1 and BRCA2 to the incidence of male breast cancer (MBC) in the United Kingdom is not known, and the importance of these genes in the increased risk of female breast cancer associated with a family history of breast cancer in a male first-degree relative is unclear. METHODS:We have c...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Basham VM,Lipscombe JM,Ward JM,Gayther SA,Ponder BA,Easton DF,Pharoah PD

    更新日期:2002-01-01 00:00:00

  • Common ataxia telangiectasia mutated haplotypes and risk of breast cancer: a nested case-control study.

    abstract:INTRODUCTION:The ataxia telangiectasia mutated (ATM) gene is a tumor suppressor gene with functions in cell cycle arrest, apoptosis, and repair of DNA double-strand breaks. Based on family studies, women heterozygous for mutations in the ATM gene are reported to have a fourfold to fivefold increased risk of breast canc...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Tamimi RM,Hankinson SE,Spiegelman D,Kraft P,Colditz GA,Hunter DJ

    更新日期:2004-01-01 00:00:00

  • Targeted therapy against Bcl-2-related proteins in breast cancer cells.

    abstract:INTRODUCTION:Bcl-2 and Bcl-xL confer resistance to apoptosis, thereby reducing the effectiveness of chemotherapy. We examined the relationship between the expression of Bcl-2 and Bcl-xL and chemosensitivity of breast cancer cells, with the aim of developing specific targeted therapy. METHODS:Four human breast cancer c...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Emi M,Kim R,Tanabe K,Uchida Y,Toge T

    更新日期:2005-01-01 00:00:00

  • Racial differences in CD8+ T cell infiltration in breast tumors from Black and White women.

    abstract:BACKGROUND:African American/Black women with breast cancer have poorer survival than White women, and this disparity persists even after adjusting for non-biological factors. Differences in tumor immune biology have been reported between Black and White women, and the tumor immune milieu could potentially drive racial ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,多中心研究


    authors: Abdou Y,Attwood K,Cheng TD,Yao S,Bandera EV,Zirpoli GR,Ondracek RP,Stein L,Bshara W,Khoury T,Ambrosone CB,Omilian AR

    更新日期:2020-06-09 00:00:00

  • Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.

    abstract:INTRODUCTION:Gene expression analysis is used to subtype breast cancers such that the most aggressive tumors are identified, but translating this into clinical practice can be cumbersome. Our goal is to develop a universal biomarker that distinguishes patients at high risk across all breast cancer subtypes. We previous...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Habibi G,Leung S,Law JH,Gelmon K,Masoudi H,Turbin D,Pollak M,Nielsen TO,Huntsman D,Dunn SE

    更新日期:2008-01-01 00:00:00

  • Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes.

    abstract:INTRODUCTION:Breast cancer subtypes exhibit different genomic aberration patterns with a tendency for high-level amplifications in distinct chromosomal regions. These genomic aberrations may drive carcinogenesis through the upregulation of proto-oncogenes. We have characterized DNA amplification at the human chromosoma...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Melchor L,Saucedo-Cuevas LP,Muñoz-Repeto I,Rodríguez-Pinilla SM,Honrado E,Campoverde A,Palacios J,Nathanson KL,García MJ,Benítez J

    更新日期:2009-01-01 00:00:00

  • Impact of intercensal population projections and error of closure on breast cancer surveillance: examples from 10 California counties.

    abstract:INTRODUCTION:In 2001, data from the California Cancer Registry suggested that breast cancer incidence rates among non-Hispanic white (nHW) women in Marin County, California, had increased almost 60% between 1991 and 1999. This analysis examines the extent to which these and other breast cancer incidence trends could ha...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Phipps AI,Clarke CA,Ereman RR

    更新日期:2005-01-01 00:00:00

  • Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.

    abstract::Recent studies indicate that constitutive signaling through the phosphatidylinositol 3'-kinase (PI3K) pathway is a cause of treatment resistance in breast cancer patients. This implies that patients with tumors that exhibit aberrant PI3K signaling may benefit from targeted pathway inhibitors. The first agents to make ...

    journal_title:Breast cancer research : BCR

    pub_type: 评论,杂志文章


    authors: Crowder RJ,Ellis MJ

    更新日期:2005-01-01 00:00:00